The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report

被引:14
作者
Engsbro, A. L. [1 ]
Simren, M. [2 ]
Bytzer, P. [1 ]
机构
[1] Univ Copenhagen, Dept Med, Koge Univ Hosp, DK-1168 Copenhagen, Denmark
[2] Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med, Inst Med, Gothenburg, Sweden
基金
英国医学研究理事会;
关键词
agreement; classification; epidemiology; irritable bowel syndrome; Rome III criteria; subtypes; FERMENTED MILK; HABIT; STABILITY; TIME;
D O I
10.1111/j.1365-2982.2012.01908.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background For comparing trials using different classifications for irritable bowel syndrome (IBS) subtypes, it is important to know whether these identify the same sub-populations. Our aim was to determine the agreement between Rome II and Rome III subtypes, and to explore whether agreement depends on the symptom reporting method. Methods Rome II IBS patients from two identical, randomized placebo-controlled trials of probiotics were included. Retrospective subtypes were based on the Rome II questionnaire. Prospective subtypes were based on diary cards for 2 weeks of run-in. Agreement was determined between: (i) retrospective Rome II and Rome III, (ii) prospective Rome II and Rome III, (iii) retrospective Rome II and prospectively Rome III, (iv) retrospective and prospective Rome II, and (v) retrospective and prospective Rome III. Key Results A total of 126 patients, 72% women, mean age 46 +/- 15 years, were included. The agreement between subtypes using the same symptom reporting method was: (i) 90.3% (? = 0.85) for retrospective subtypes, and (ii) 84% (? = 0.76) for prospective subtypes. The agreement between subtypes using different symptom reporting methods was, (iii) 49% (? = 0.23) for retrospective Rome II and prospective Rome III, (iv) 51% (? = 0.26) for Rome II subtypes, and (v) 41% (? = 0.25) for Rome III subtypes. Conclusions & Inferences Agreement between Rome II and Rome III subtypes is good to very good when using the same symptom reporting method. When mixing methods, agreement is only fair even within the same classification. This has implications for comparison of trials using different symptom reporting methods for subtyping.
引用
收藏
页码:604 / e266
页数:9
相关论文
共 25 条
[1]  
Altman DG, 1990, PRACTICAL STAT MED R, DOI DOI 10.1201/9780429258589
[2]  
[Anonymous], ROME
[3]   Epidemiology of IBS [J].
Choung, Rok Seon ;
Locke, G. Richard, III .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2011, 40 (01) :1-+
[4]   Discrepancy between recalled and recorded bowel habits in irritable bowel syndrome [J].
Coletta, M. ;
Di Palma, L. ;
Tomba, C. ;
Basilisco, G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (02) :282-288
[5]   Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions [J].
Deiteren, A. ;
Camilleri, M. ;
Bharucha, A. E. ;
Burton, D. ;
McKinzie, S. ;
Rao, A. S. ;
Zinsmeister, A. R. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2010, 22 (04) :413-+
[6]  
Deiteren A, 2010, NEUROGASTROENT MOTIL, V22, pe95
[7]   Irritable Bowel Syndrome Subtypes Defined by Rome II and Rome III Criteria are Similar [J].
Dorn, Spencer D. ;
Morris, Carolyn B. ;
Hu, Yuming ;
Toner, Brenda B. ;
Diamant, Nicholas ;
Whitehead, William E. ;
Bangdiwala, Shrikant I. ;
Drossman, Douglas A. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (03) :214-220
[8]   A prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator [J].
Drossman, DA ;
Morris, CB ;
Hu, YM ;
Toner, BB ;
Diamant, N ;
Leserman, J ;
Shetzline, M ;
Dalton, C ;
Bangdiwala, SI .
GASTROENTEROLOGY, 2005, 128 (03) :580-589
[9]   Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification [J].
Engsbro, A. L. ;
Simren, M. ;
Bytzer, P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (03) :350-359
[10]   Subtyping the irritable bowel syndrome by predominant bowel habit:: Rome II versus Rome III [J].
Ersryd, A. ;
Posserud, I. ;
Abrahamsson, H. ;
Simren, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (06) :953-961